Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.
Also called NCT05473520
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT05473520
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Malaysia, Singapore
- Registry status
- Recruiting
Technical summary
Registry record NCT05473520. Randomized; quadruple masking; primary purpose treatment. Start 2023-05-24 (actual); primary completion 2030-01-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
- Acronym
- Doxy-TB
- Condition
- Tuberculosis
- Condition
- Acute Coronary Syndrome
- Condition
- Pulmonary Hypertension (Diagnosis)
- Intervention (Drug)
- Doxycycline
- Intervention (Drug)
- Placebo
- Lead sponsor
- National University Hospital, Singapore
- Collaborator
- Tan Tock Seng Hospital
- Collaborator
- Hospital Queen Elizabeth, Malaysia
- Collaborator
- National University of Singapore
- Collaborator
- University Malaysia Sabah
- Collaborator
- Menggatal Health Clinic, Sabah, Malaysia
- Collaborator
- Luyang Health Clinic, Sabah, Malaysia
Record details
- Record id
cardio:ct-nct05473520- Content hash
f1c1f0f8ddbf08b544f47ae11fd230046bf7f7d57b89b5f1d7e6a0a2b936a135